Welcome to our dedicated page for Travere Therapeutics news (Ticker: TVTX), a resource for investors and traders seeking the latest updates and insights on Travere Therapeutics stock.
News and updates for Travere Therapeutics, Inc. (TVTX) center on its work as a biopharmaceutical company focused on rare kidney, liver and metabolic diseases. Company announcements frequently highlight progress with FILSPARI (sparsentan), an oral, non-immunosuppressive therapy approved to slow kidney function decline in adults with primary IgA nephropathy (IgAN), and under supplemental FDA review as a potential treatment for focal segmental glomerulosclerosis (FSGS).
Investors following TVTX news can track regulatory milestones such as FDA review timelines, PDUFA target action dates and review extensions for the FILSPARI sNDA in FSGS. Travere also reports new clinical data from the Phase 3 DUPLEX and Phase 2 DUET studies in FSGS, as well as from PROTECT, SPARTAN and real-world analyses in IgAN. These updates often focus on proteinuria reduction, kidney function outcomes and correlations between biomarker changes and long-term kidney failure risk.
Travere’s news flow includes financial results and preliminary revenue updates, typically furnished via press releases and Form 8‑K filings, along with commentary on commercial performance of FILSPARI in IgAN. The company also issues releases on pipeline developments, including the planned restart of the pivotal Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria (HCU) and long-term metabolite reduction data from the COMPOSE study.
Additional news items cover partnership activities with CSL Vifor and Renalys Pharma, anticipated regional filings and launches, and Travere’s participation in major medical and investor conferences such as the American Society of Nephrology Kidney Week and large healthcare investment meetings. This page aggregates these developments so readers can follow how clinical, regulatory, commercial and partnership events may shape the company’s rare disease portfolio over time.
Travere Therapeutics has completed its previously announced public offering of 8,984,375 shares of common stock at $16.00 per share, including 1,171,875 shares from the full exercise of underwriters' option. The offering generated gross proceeds of approximately $143.8 million before deducting underwriting discounts and expenses. Jefferies and Leerink Partners served as joint book-running managers, with Wedbush PacGrow as co-manager. The offering was made pursuant to a shelf registration statement that became effective on August 1, 2024.
Travere Therapeutics (Nasdaq: TVTX) has announced the pricing of a public offering of 7,812,500 shares of common stock at $16.00 per share. The offering is expected to generate gross proceeds of $125.0 million before deducting underwriting costs and expenses. The company has granted underwriters a 30-day option to purchase up to an additional 1,171,875 shares. The offering, managed by Jefferies and Leerink Partners with Wedbush PacGrow as co-manager, is expected to close on November 12, 2024.
Travere Therapeutics (Nasdaq: TVTX) has announced plans for an underwritten public offering of its common stock. The company will offer all shares, with an additional 30-day option for underwriters to purchase up to 15% more shares. Jefferies and Leerink Partners are serving as joint book-running managers. The offering will be made pursuant to an automatically effective shelf registration statement filed with the SEC on August 1, 2024. The completion, size, and terms of the offering are subject to market conditions and cannot be assured.
Travere Therapeutics (NASDAQ: TVTX) has announced its participation in two major healthcare investor conferences this November. The company will present at the Guggenheim Securities Healthcare Innovation Conference on Monday, November 11, 2024, at 2:30 p.m. ET, and at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 8:30 a.m. GMT. Live webcasts of both presentations will be available on Travere's investor relations website, with replays accessible for up to 30 days after each event.
Travere Therapeutics (NASDAQ: TVTX) reported Q3 2024 financial results, highlighting FILSPARI's full FDA approval as the only non-immunosuppressive treatment for IgAN. Net product sales reached $61.0 million, with FILSPARI contributing $35.6 million. Total revenue was $62.9 million. The company received 505 new patient start forms for FILSPARI during Q3. R&D expenses decreased to $51.7 million from $60.6 million year-over-year. The company reported a net loss of $54.8 million ($0.70 per share) and held $277.4 million in cash and equivalents as of September 30, 2024.
Travere Therapeutics presented new data for FILSPARI (sparsentan) at ASN Kidney Week 2024, showing significant clinical benefits in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). The SPARTAN Study demonstrated nearly 60% of first-line IgAN patients achieved complete remission, with approximately 70% proteinuria reduction over 24 weeks. The SPARTACUS Study showed FILSPARI's effectiveness in combination therapy, with one-third of patients achieving 50% proteinuria reduction when added to SGLT2i. In genetic FSGS patients, typically treatment-resistant, FILSPARI delivered sustained proteinuria reduction and long-term kidney health benefits.
Travere Therapeutics (NASDAQ: TVTX) has announced its plans to report third quarter 2024 financial results on Thursday, October 31, 2024, before the U.S. financial markets open. The company will host a conference call and webcast at 8:30 a.m. ET to discuss the financial results and provide a general business update.
Investors and interested parties can access the webcast and dial-in information on the Investor page of Travere's website at ir.travere.com/events-presentations. An archived version of the call will be available for 30 days on the company's website following the live webcast.
Travere Therapeutics and CSL Vifor have announced that Swissmedic has granted temporary marketing authorization for FILSPARI® (sparsentan) for the treatment of adults with primary IgA nephropathy (IgAN) with specific urine protein excretion levels. The approval is based on results from the Phase 3 PROTECT Trial, which showed statistically significant and clinically meaningful outcomes.
FILSPARI offers a once-daily, oral, non-immunosuppressive treatment that targets kidney damage directly and has demonstrated superior results compared to maximally dosed irbesartan. This approval follows full marketing approval by the FDA in September 2024 and conditional marketing authorization by the EMA in April 2024.
In 2021, Travere Therapeutics granted CSL Vifor exclusive commercialization rights for FILSPARI in Europe, Australia and New Zealand. Both companies express enthusiasm about providing access to this innovative treatment for the Swiss IgAN community.
CSL Vifor and Travere Therapeutics announced that Swissmedic has granted temporary marketing authorization for FILSPARI (sparsentan) to treat adults with primary IgA nephropathy (IgAN) with specific urine protein levels. The approval is based on the phase-III PROTECT trial results. This follows full marketing approval by the FDA in September 2024 and conditional marketing authorization by the EMA in April 2024.
Emmanuelle Lecomte Brisset of CSL highlighted the high unmet medical need for targeted IgAN therapy. Eric Dube of Travere Therapeutics emphasized FILSPARI's benefits as a non-immunosuppressive, once-daily oral treatment that can provide superior results compared to maximally dosed irbesartan.
Travere Therapeutics (Nasdaq: TVTX) will present 11 abstracts at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, from October 23-27, 2024. The presentations will showcase new data on FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy (IgAN).
Key highlights include:
- Efficacy and safety results of FILSPARI as a first-line treatment in newly diagnosed IgAN patients (SPARTAN Study)
- Analysis of FILSPARI's clinical benefit in IgAN regardless of baseline proteinuria (PROTECT Study)
- Patient-reported outcomes from the PROTECT and DUPLEX Studies
- Data on FILSPARI in combination with SGLT2 inhibitors
- A late-breaking presentation on outcomes in patients with genetic focal segmental glomerulosclerosis (gFSGS) from the DUPLEX Study
The presentations will cover various aspects of FILSPARI's use in IgAN and FSGS, including its efficacy as a first-line treatment and in combination with other therapies.